Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

APP heparin manufacturing facility approved

Executive Summary

APP Pharmaceuticals announces Aug. 18 that FDA approved a facility in Barceloneta, Puerto Rico for the manufacture of three product codes of Heparin Sodium Injection. Currently the sole supplier of heparin in the U.S. in the wake of Baxter's heparin contamination fiasco, APP said approval of the third manufacturing facility will free up its other facilities to fulfill outstanding orders. The German health care products and services company Fresenius announced last month a $4.6 billion acquisition of APP - a buyout price that could increase if APP profits are higher than projected (1"The Pink Sheet," July 14, 2008, p. 17)

You may also be interested in...



Fresenius Fearlessly Acquires Sole Supplier Of Heparin in U.S.

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at 1http://invivoblog.blogspot.com/.

Qiagen’s Ambitions: Standing Alone & Strengthening Infectious Disease Portfolio

Antoine Marchal, Franchise Head PCR Core Labs - BA Molecular Diagnostics at Qiagen outlines how NeuModx will strengthen its position in the infectious disease space.

 

Bayer's Job Cuts And Flat 2021 Sales Outlook Disappoint

Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel